Skip Nav Destination
Issues
1 May 2012
-
Cover Image
Cover Image
Jag1, a Notch ligand, enhances proliferation of adrenocortical carcinoma (ACC) cells. Pictured are ACC cells expressing dsRedII (Red) cocultured with ACC cells coexpressing GFP (GFP) and Jag1 shRNA. With cells plated at a ratio of 90% to 10% (red and green cells, respectively), Jag1 knockdown was found to diminish ACC cell proliferation in a non–cell-autonomous manner consistent with a Notch receptor–dependent effect of Jag1 on adrenal cancer growth. For details, see the article by Simon and colleagues on page 2452 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
Molecular Pathways
Review
Human Cancer Biology
Detection and Characterization of a Novel Subset of CD8+CD57+ T Cells in Metastatic Melanoma with an Incompletely Differentiated Phenotype
Richard C. Wu; Shujuan Liu; Jessica A. Chacon; Sheng Wu; Yufeng Li; Pariya Sukhumalchandra; James L. Murray; Jeffrey J. Molldrem; Patrick Hwu; Hanspeter Pircher; Gregory Lizée; Laszlo G. Radvanyi
Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients
Elliot L. Servais; Christos Colovos; Luis Rodriguez; Adam J. Bograd; Jun-ichi Nitadori; Camelia Sima; Valerie W. Rusch; Michel Sadelain; Prasad S. Adusumilli
IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma
Daniel Gorovets; Kasthuri Kannan; Ronglai Shen; Edward R. Kastenhuber; Nasrin Islamdoust; Carl Campos; Elena Pentsova; Adriana Heguy; Suresh C. Jhanwar; Ingo K. Mellinghoff; Timothy A. Chan; Jason T. Huse
Cancer Therapy: Preclinical
The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
Kim H.T. Paraiso; H. Eirik Haarberg; Elizabeth Wood; Vito W. Rebecca; Y. Ann Chen; Yun Xiang; Antoni Ribas; Roger S. Lo; Jeffrey S. Weber; Vernon K. Sondak; Jobin K. John; Amod A. Sarnaik; John M. Koomen; Keiran S.M. Smalley
Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
Giorgia Migliardi; Francesco Sassi; Davide Torti; Francesco Galimi; Eugenia R. Zanella; Michela Buscarino; Dario Ribero; Andrea Muratore; Paolo Massucco; Alberto Pisacane; Mauro Risio; Lorenzo Capussotti; Silvia Marsoni; Federica Di Nicolantonio; Alberto Bardelli; Paolo M. Comoglio; Livio Trusolino; Andrea Bertotti
Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts
Mark D. Walsh; Suzan K. Hanna; Jeremy Sen; Sumit Rawal; Carolina B. Cabral; Alex V. Yurkovetskiy; Robert J. Fram; Timothy B. Lowinger; William C. Zamboni
Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
Celina García-García; Yasir H. Ibrahim; Violeta Serra; Maria Teresa Calvo; Marta Guzmán; Judit Grueso; Claudia Aura; José Pérez; Katti Jessen; Yi Liu; Christian Rommel; Josep Tabernero; José Baselga; Maurizio Scaltriti
Imaging, Diagnosis, Prognosis
Proximal Fluid Proteome Profiling of Mouse Colon Tumors Reveals Biomarkers for Early Diagnosis of Human Colorectal Cancer
Remond J.A. Fijneman; Meike de Wit; Maral Pourghiasian; Sander R. Piersma; Thang V. Pham; Marc O. Warmoes; Mehrdad Lavaei; Chloe Piso; Fiona Smit; Pien M. Delis-van Diemen; Sietze T. van Turenhout; Jochim S. Terhaar sive Droste; Chris J.J. Mulder; Marinus A. Blankenstein; Els C. Robanus-Maandag; Ron Smits; Riccardo Fodde; Victor W.M. van Hinsbergh; Gerrit A. Meijer; Connie R. Jimenez
Cancer Therapy: Clinical
Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors
Aung Naing; Patricia LoRusso; Siqing Fu; David S. Hong; Pete Anderson; Robert S. Benjamin; Joseph Ludwig; Helen X. Chen; Laurence A. Doyle; Razelle Kurzrock
The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial
Jason J. Luke; David R. D'Adamo; Mark A. Dickson; Mary Louise Keohan; Richard D. Carvajal; Robert G. Maki; Elisa de Stanchina; Elgilda Musi; Samuel Singer; Gary K. Schwartz
A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
Klaus Mross; Annette Frost; Simone Steinbild; Susanne Hedbom; Martin Büchert; Ulrike Fasol; Clemens Unger; Jörn Krätzschmar; Roland Heinig; Oliver Boix; Olaf Christensen
Phase I Trial of Intraperitoneal Pemetrexed, Cisplatin, and Paclitaxel in Optimally Debulked Ovarian Cancer
Setsuko K. Chambers; H-H. Sherry Chow; Mike F. Janicek; Janiel M. Cragun; Kenneth D. Hatch; Haiyan Cui; Cynthia Laughren; Mary C. Clouser; Janice L. Cohen; Heather M. Wright; Nisreen Abu Shahin; David S. Alberts
Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
Steven G. DuBois; Louis Chesler; Susan Groshen; Randall Hawkins; Fariba Goodarzian; Hiroyuki Shimada; Greg Yanik; Michael Tagen; Clinton Stewart; Yael P. Mosse; John M. Maris; Denice Tsao-Wei; Araz Marachelian; Judith G. Villablanca; Katherine K. Matthay
A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
Udai Banerji; Leni van Doorn; Dionysis Papadatos-Pastos; Rebecca Kristeleit; Phillip Debnam; Matthew Tall; Adam Stewart; Florence Raynaud; Michelle Dawn Garrett; Martin Toal; Leon Hooftman; Johann Sebastian De Bono; Jaap Verweij; Ferry ALM Eskens
Predictive Biomarkers and Personalized Medicine
A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors
Marcus Schmidt; Birte Hellwig; Seddik Hammad; Amnah Othman; Miriam Lohr; Zonglin Chen; Daniel Boehm; Susanne Gebhard; Ilka Petry; Antje Lebrecht; Cristina Cadenas; Rosemarie Marchan; Joanna D. Stewart; Christine Solbach; Lars Holmberg; Karolina Edlund; Hanna Göransson Kultima; Achim Rody; Anders Berglund; Mats Lambe; Anders Isaksson; Johan Botling; Thomas Karn; Volkmar Müller; Aslihan Gerhold-Ay; Christina Cotarelo; Martin Sebastian; Ralf Kronenwett; Hans Bojar; Hans-Anton Lehr; Ugur Sahin; Heinz Koelbl; Mathias Gehrmann; Patrick Micke; Jörg Rahnenführer; Jan G. Hengstler
Common PIK3CA Mutants and a Novel 3′ UTR Mutation Are Associated with Increased Sensitivity to Saracatinib
John J. Arcaroli; Kevin S. Quackenbush; Rebecca W. Powell; Todd M. Pitts; Anna Spreafico; Marileila Varella-Garcia; Lynne Bemis; Aik Choon Tan; Jaclyn M. Reinemann; Basel M. Touban; Arvind Dasari; S. Gail Eckhardt; Wells A. Messersmith
Letters to the Editor
Corrections
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds